Cytonics novel “CYT-108” biologic therapy may be the first and only disease-modifying treatment for osteoarthritis.
🧬 CYT-108: a genetically engineered variant of the Alpha-2-Macroglobulin protein.
Here’s how it works.
CYT-108 is a synthetic (“recombinant”) variant of the naturally occurring Alpha-2-Macroglobulin (A2M) protein. A2M is found in the blood, and plays a role in blood clotting through a mechanism called “protease inhibition.” Think of proteases as little “Pac Men” that chew through other proteins… including those that provide cartilage with its structure. The first iteration of our technology, the “APIC” therapy, selectively enriched A2M from patients’ own blood stream for direct injection into arthritic joints. Having treated over 8,000 patients to date, the clinical and commercial success of our first FDA-approved technology is a testament to the power of A2M as a therapy for osteoarthritis.
Emboldened by this knowledge, we have developed a genetically engineered version of the natural A2M that is 3x more potent than the A2M found in your blood. This synthetic A2M, “CYT-108,” can be manufactured in a laboratory, distributed globally, and delivered in supra-physiological (i.e., very high) concentrations for maximum efficacy. All of these characteristics are what make CYT-108 a significant improvement over the natural A2M concentrated in the APIC therapy.
Simply put, we know A2M works. Now, we just have to prove that our CYT-108 synthetic variant is even better.
In our next post, we will introduce you to the Executive Team and protagonists of this David v. Goliath story.
Ready to become a shareholder? Visit invest.cytonics.com.
This communication may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they contain hypothetical illustrations of mathematical principles, are meant for illustrative purposes, and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.
Leave a Reply